[et_pb_section fb_built=”1″ next_background_color=”#ffffff” _builder_version=”4.27.4″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#001970 0%|#303f9f 100%” bottom_divider_style=”wave2″ bottom_divider_height=”50px” bottom_divider_height_tablet=”50px” bottom_divider_height_phone=”25px” bottom_divider_height_last_edited=”on|phone” da_disable_devices=”off|off|off” locked=”off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][dipi_dual_heading first_heading=”Prof Andrew Spencer” second_heading=”Head of the Malignant Haematology, Transplantation and Cellular Therapy Service, The Alfred Hospital” heading_display=”column” _builder_version=”4.27.4″ _module_preset=”default” first_heading_font=”|700|||||||” first_heading_text_color=”#ffffff” first_heading_font_size=”40px” second_heading_text_color=”#E8EAF6″ first_heading_font_size_tablet=”40px” first_heading_font_size_phone=”30px” first_heading_font_size_last_edited=”on|phone” second_heading_font_size_tablet=”” second_heading_font_size_phone=”” second_heading_font_size_last_edited=”on|phone” global_colors_info=”{}”][\/dipi_dual_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” da_disable_devices=”off|off|off” locked=”off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/meeting.anztct.org.au\/2025\/wp-content\/uploads\/sites\/4\/2025\/07\/anztct-2025-andrew-spencer-500px.jpg” alt=”Andrew Spencer” title_text=”Andrew Spencer” _builder_version=”4.27.4″ _module_preset=”default” border_radii=”on|50%|50%|50%|50%” border_width_all=”5px” border_color_all=”#303F9F” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][dipi_dual_heading first_heading=”Speaker” second_heading=”About Prof Andrew Spencer” heading_display=”column” fh_style=”background” first_heading_color=”#E8EAF6″ _builder_version=”4.27.4″ _module_preset=”default” first_heading_font=”|||on|||||” first_heading_font_size=”11px” first_heading_letter_spacing=”1px” text_orientation=”left” custom_margin=”||10px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][\/dipi_dual_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]Professor Andrew Spencer is Head of the Malignant Haematology, Transplantation and Cellular Therapy Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group (MRG), all in Melbourne, Australia. He moved to The Alfred Hospital in 1999 where he established an independent translational research program and a first-in-human and early phase haematology clinical research unit with currently 140 open trials with 400 registered patients. He has >320 peer reviewed publications with over 32,000 citations. Since 2020 he has been an invited speaker at 50 international meetings on genomics, therapeutics and disease monitoring in multiple myeloma. He serves on the scientific advisory boards of the International Myeloma Foundation and the International Myeloma Working Group. He established and Chairs the ANZ Myeloma and Related Diseases Registry (MRDR), the APAC MRDR and the associated M1000 liquid biopsy biobank. He established the Australasian Myeloma Research Consortium (AMaRC) in 2016. He has recently been invited to join the board of the European Myeloma Network.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Head of the Malignant Haematology, Transplantation and Cellular Therapy Service, The Alfred Hospital<\/p>\n","protected":false},"author":8,"featured_media":486,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"2880","footnotes":""},"categories":[12],"tags":[],"dipi_cpt_category":[],"class_list":["post-496","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-speaker"],"yoast_head":"\n